SCHEMBL23913071

SCHEMBL23913071

Cn1nc(-c2ccc(OCc3ccc(Cl)cc3)c(-c3cccc(C#N)c3)c2O)cc1C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 3/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.41
XDH P47989 2/20 0.39
CCR5 P51681 1/20 0.39
MRGPRX4 Q96LA9 3/20 0.39
ALOX5 P09917 1/20 0.39
ALOX5AP P20292 1/20 0.39
PLK1 P53350 1/20 0.36
PSD A5PKW4 1/20 0.36
USP7 Q93009 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
TGFBR1 P36897 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21786592 0.89 PTGER1 (0.39) PTGER1CCR5MRGPRX4PLK1MAPT
SCHEMBL22825455 0.86 PTGER1 (0.36) PTGER1CCR5MRGPRX4PLK1MAPT
SCHEMBL22791092 0.86 PTGER1 (0.35) PTGER1CCR5MRGPRX4PLK1KMT2A
SCHEMBL24127547 0.85 MAPT (0.39) PTGER1CCR5MEN1LMNAMAPT
SCHEMBL21786412 0.85 MRGPRX4 (0.40) PTGER1PTGDR2XDHCCR5MRGPRX4
SCHEMBL22791325 0.83 PTGDR2 (0.44) PTGER1PTGDR2XDHCCR5MRGPRX4
SCHEMBL23913085 0.79 MRGPRX4 (0.40) PTGER1PTGDR2CCR5MRGPRX4ALOX5
SCHEMBL22791194 0.78 MRGPRX4 (0.39) PTGER1XDHMRGPRX4ALOX5ALOX5AP
SCHEMBL19319843 0.76 ALOX5AP (0.42) PTGER1PTGDR2ALOX5ALOX5APKMT2A
SCHEMBL21786410 0.75 MRGPRX4 (0.41) PTGER1PTGDR2XDHCCR5MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11142504-B2 Substituted heterocycles as c-MYC targeting agents NORTHWESTERN UNIVERSITY (US) 2021-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11142504-B2 Substituted heterocycles as c-MYC targeting agents MYC, MYCBP, MYCBP2 PTGER1 4862/4885PTGDR2 4007/4885XDH 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.